Charles River Laboratories International, Inc. $CRL Stock Purchased by Sterling Capital Management LLC

Key Points

• Sterling Capital Management increased its CRL stake by 350.3% in the third quarter, bringing its holdings to 6,642 shares valued at approximately $1.96 million. Institutional investors and hedge funds collectively own 98.91% of the company.
• Company insiders sold 94,127 shares worth approximately $26.8 million over the past 90 days, including substantial sales by EVP Shannon Parisotto and Director James C. Foster under pre-arranged trading plans.
• Charles River Laboratories exceeded quarterly earnings and revenue expectations, reporting $3.02 in adjusted EPS on $1 billion in revenue, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $302.33.

Sterling Capital Management LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 350.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,642 shares of the medical research company's stock after acquiring an additional 5,167 shares during the period. Sterling Capital Management LLC's holdings in Charles River Laboratories International were worth $1,959,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of CRL. Yousif Capital Management LLC lifted its position in shares of Charles River Laboratories International by 721.8% during the 3rd quarter. Yousif Capital Management LLC now owns 43,367 shares of the medical research company's stock worth $12,794,000 after buying an additional 38,090 shares during the period. Compass Wealth Management LLC bought a new stake in Charles River Laboratories International in the third quarter valued at $69,000. Cardinal Capital Management raised its stake in Charles River Laboratories International by 4.9% during the third quarter. Cardinal Capital Management now owns 11,756 shares of the medical research company's stock worth $3,468,000 after acquiring an additional 550 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in Charles River Laboratories International by 197.3% during the third quarter. Crossmark Global Holdings Inc. now owns 12,773 shares of the medical research company's stock worth $3,768,000 after acquiring an additional 8,476 shares in the last quarter. Finally, Physician Wealth Advisors Inc. lifted its holdings in Charles River Laboratories International by 127.9% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company's stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Charles River Laboratories International

In other news, EVP Shannon Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total value of $1,327,098.00. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at $1,264,241. This trade represents a 51.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James C. Foster sold 33,561 shares of the business's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at approximately $9,478,800. This represents a 51.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 94,127 shares of company stock worth $26,776,516. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $345.08 on Monday. The firm has a market cap of $16.47 billion, a price-to-earnings ratio of -71.15, a price-to-earnings-growth ratio of 3.23 and a beta of 1.40. The stock's 50-day moving average is $294.35 and its 200-day moving average is $233.67. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $351.21. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. Charles River Laboratories International's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRL has been the topic of a number of recent analyst reports. BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a research note on Wednesday, July 1st. Zacks Research raised shares of Charles River Laboratories International from a "hold" rating to a "strong-buy" rating in a research report on Friday, October 2nd. Mizuho boosted their price objective on Charles River Laboratories International from $264.00 to $295.00 and gave the company a "neutral" rating in a research report on Friday, September 25th. Deutsche Bank Aktiengesellschaft increased their target price on Charles River Laboratories International from $300.00 to $320.00 and gave the stock a "buy" rating in a research note on Friday, September 25th. Finally, Barclays raised their target price on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the stock an "overweight" rating in a report on Friday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Charles River Laboratories International has a consensus rating of "Moderate Buy" and an average target price of $302.33.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.